James Joe, Jose James, Gafoor V Abdul, Smita B, Balaram Neetha
Department of Neurology Government Medical College Kozhikode India.
Neurol Clin Neurosci. 2021 Sep;9(5):402-405. doi: 10.1111/ncn3.12537. Epub 2021 Jul 21.
ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 (COVID-19) vaccine. Rare cases of serious adverse events have been reported with this vaccine. We report three patients who developed Guillain-Barré syndrome following ChAdOx1 nCoV-19 vaccination, who did not have active or prior COVID-19 infection. The neurological illness in all patients had an onset of 11-13 days after the first dose of vaccine. All were characterized by sensorimotor weakness of the upper and lower limbs, with facial diplegia in one and dysautonomia in the other. Nerve conduction studies were consistent with demyelination in two and axonopathy in one. Cerebrospinal fluid analysis showed albuminocytological dissociation in two patients. All patients had moderate-to-severe disability. They were treated with intravenous immunoglobulin, with stabilization of the disease. Proper monitoring and prompt reporting of such cases is required to ensure safety of the vaccine.
ChAdOx1 nCoV-19是一种有效且耐受性良好的2019冠状病毒病（COVID-19）疫苗。已有关于该疫苗罕见严重不良事件的报告。我们报告了3例在接种ChAdOx1 nCoV-19疫苗后发生吉兰-巴雷综合征的患者，这些患者既往无活动性或既往COVID-19感染。所有患者的神经系统疾病均在接种第一剂疫苗后11至13天发病。所有患者均以上下肢感觉运动无力为特征，其中1例伴有双侧面瘫，另1例伴有自主神经功能障碍。神经传导研究结果显示，2例符合脱髓鞘改变，1例符合轴索性神经病。脑脊液分析显示，2例患者存在蛋白细胞分离现象。所有患者均有中度至重度残疾。他们接受了静脉注射免疫球蛋白治疗，病情得到稳定。需要对此类病例进行适当监测并及时报告，以确保疫苗的安全性。
